-
SpeichernDas Eingabefeld wird
gespeichert wenn Sie das Feld
verlassen oder hier klicken.↓
Börse Xetra FrankfurtEURISIN US75886FAE79-
Regeneron Pharmaceuticals Inc.Börse NasdaqISIN US75886F1075 WKN: 881535Symbol REGN
-
Regeneron PharmaceuticalsBörse Xetra FrankfurtISIN US75886FAE79EURSymbol RGO
-
Regeneron PharmaceuticalsBörse Börse FrankfurtEURSymbol RGO
-
Regeneron PharmaceuticalsBörse Börse BerlinEURSymbol RGO
-
Regeneron PharmaceuticalsBörse Börse StuttgartEURSymbol RGO
-
Regeneron PharmaceuticalsBörse Börse MünchenEURSymbol RGO
-
REGENERON PHARMACEUTICALSBörse Quotrix System der Börse DüsseldorfEURSymbol RGO
-
REGENERON PHARMACEUTICALSBörse Börse DüsseldorfEURSymbol RGO
-
REGENERON PHARMACEUTICALSBörse Tradegate System der Deutsche Börse AG (60%)EURSymbol RGO
-
REGENERON PHARMACEUTICALSBörse Gettex System der Börse MünchenEURSymbol RGO
-
Regeneron PharmaceuticalsBörse Börse Stuttgart
-
Regeneron PharmaceuticalsBörse NasdaqISIN US75886F1075 WKN: 881535USDSymbol REGN
-
Regeneron PharmaceuticalsBörse Bolsa Mexicana de Valore Mexiko-StadtMXNISIN US75886FAF45
-
Regeneron Pharmaceuticals, Inc.Börse London Stock Exchange
-
Regeneron Pharmaceuticals, Inc.Börse BVMF
-
Regeneron Pharmaceuticals, Inc.Börse Bolsa Mexicana de Valore Mexiko-Stadt
-
ISIN US75886FAE79
Symbol RGO
Währung
EUR
Börse
Xetra Frankfurt Zeitzone: Europe/Berlin
Firmenname
Regeneron Pharmaceuticals, Inc
Marktkapitalisierung
54.389.120.217 (+- 6%)
Die einen sagen so, die anderen so... Es gibt 3 Datenquellen:
54.622.801.920 oder 57.888.000.000 oder 50.656.558.731
Mitarbeiter
10.207 (+- 19%)
Die einen sagen so, die anderen so... Es gibt 2 Datenquellen:
8.314 oder 12.099 Mitarbeiter
Anzahl Aktien
104.857.294
KGV
19.08 (+- 2%)
Die einen sagen so, die anderen so... Es gibt 2 Datenquellen:
18.76 oder 19.4
EBITDA 3.348.999.936
PEGRatio 0.9353
Buchwert 96.011
Aktionärsstruktur der Regeneron Pharmaceuticals, Inc
Portrait der Regeneron Pharmaceuticals Aktie
Das Unternehmen Regeneron Pharmaceuticals, Inc aus USA beschäftigt 10.207 Mitarbeiter und ist in den Bereichen Chemie & Pharma, Biotechnologie & Pharmazeutika, Biotechnologie, Pharma tätig.
Das Unternehmen Regeneron Pharmaceuticals, Inc ist in mehr als 79 ETFs enthalten und somit ein eher allgemein bekannter Wert. Der Spitzenreiter VanEck Vectors Biotech ETF gewichtet Regeneron Pharmaceuticals mit 5,83% im ETF.
Es ist auch möglich über Anleihen zu investieren. Hier findest du alle Regeneron Pharmaceuticals Anleihen auf einen Blick.
Entdecke die 6 ETFs in denen Regeneron Pharmaceuticals, Inc am höchsten gewichtet ist Insgesamt in 79 ETFs enthalten
Dir gefallen die Informationen zu Regeneron Pharmaceuticals?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn Ihr meine Arbeit unterstützen möchtet, dann eröffnet gerne ein mindestens 3 Jahre lang kostenloses Depot bei der comdirect. Wenn du das über diesen Link machst unterstützt du auch meine Tochter Zoe, da es Ihr Juniordepot ist. Sie erhält 20 und bei einem aktiven ETF- oder Aktien-Sparplan bleibt dein Depot auch danach kostenfrei:
Zur Comdirect
Dir gefallen die Informationen zu Regeneron Pharmaceuticals?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn du meine Arbeit unterstützen möchtest, dann eröffne ein kostenloses und unverbindliches Depot bei BUX Zero mit der Möglichkeit kostenlos US-Aktien und für einen Euro viele weitere Aktien aus Deutschland, Belgien, Niederlande, sterreich oder UK zu kaufen. Wenn du das über meinen Link machst, bekommen wir beide eine gratis Aktie geschenkt:
Zu BUX Zero
Dir gefallen die Informationen zu Regeneron Pharmaceuticals?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn Ihr meine Arbeit unterstützen möchtet, dann eröffnet gerne ein kostenloses und unverbindliches Depot bei Trade Republic mit der Möglichkeit kostenlos Aktien zu besparen. Wenn du das über meinen Link machst, bekommst du und ich bei deinem ersten Wertpapierkauf 15 von Trade Republic geschenkt:
Zu Trade Republic
Dir gefallen die Informationen zu Regeneron Pharmaceuticals?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn du meine Arbeit unterstützen möchtest, dann eröffne gerne ein kostenloses und unverbindliches Depot bei der ING Diba. Ich erhalte 20 wenn du daraufhin dann zum Beispiel einen Aktien-Sparplan anlegst oder etwas kaufst:
Zur ING Diba
186 News & Informationen zur Regeneron Pharmaceuticals Aktie
Here is a Market Recap for today Thursday, July 8, 2021 : StockMarket
PsychoMarket Recap – Thursday, July 8, 2021 Stocks dipped across the board today, putting a stop to the recent record-setting rally that has seen …
Biotech 'Strikes Again,' Identifies Gene Mutation that Protects Against Obesity
4 Healthcare Stocks to Buy for Growth and Value By StockNews
4 Healthcare Stocks to Buy for Growth and Value
Pharmaceutical Executive® APEX Awards Announces 2021 Finalists
/PRNewswire/ — Pharmaceutical Executive®, a leading multimedia platform for industry leaders to exchange experiences and insights about innovative business…
Pharmaceutical Executive® APEX Awards Announces 2021 Finalists
CRANBURY, N.J., July 8, 2021 /PRNewswire/ — Pharmaceutical Executive®, a leading multimedia platform for industry leaders to exchange experiences and
Regeneron to Report Second Quarter 2021 Financial and Operating Results and Host Conference Call and Webcast on August 5, 2021
TARRYTOWN, N.Y., July 7, 2021 /PRNewswire/ — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its second quarte…
Outlook On The Pulmonary Drugs Global Market To 2026 – Rising Prevalence Of Pulmonary Diseases Is Driving Growth
DUBLIN, July 7, 2021 /PRNewswire/ — The “Global Pulmonary Drugs Market (2021-2026) by Drug Class, Indication, Distribution Channel, Geography, Competitive
Will an Increase in Vaccinations Hurt Regeneron's COVID Treatment Sales?
The antibody cocktail treats people with mild-to-moderate illness.
This News May Mean Billions for Regeneron
Regeneron's COVID-19 treatment is getting easier to administer — and produce.
Regeneron Pharmaceuticals (REGN) Presents At Guggenheim's Biopharma Next Decade: Views from the Top on Global Strategy and Innovation – Slideshow (NASDAQ:REGN)
The following slide deck was published by Regeneron Pharmaceuticals, Inc.
3 Reasons to Invest in Regeneron Pharmaceuticals (REGN) Now
Regeneron's (REGN) efforts to expand the label of its approved drugs and concurrently develop the pipeline are impressive and makes it a good bet for investors, for now.
Regeneron Pharmaceuticals : Genetics Center Discovers GPR75 Gene Mutations that Protect Against Obesity
TARRYTOWN, N.Y., July 1, 2021 /PRNewswire/ —
Publication in Science reports that people with these protective mutations have 54% reduced risk of obesity
Regeneron used its… | July 1, 2021
4 Unstoppable Biotech Stocks to Buy Right Now By StockNews
4 Unstoppable Biotech Stocks to Buy Right Now
Can Intellia Therapeutics Turn Exciting Trial Results into Profits?
New proof-of-concept results are a big deal for the medical community, but what about for your portfolio?
Intellia Shares Rise 49% on 'Landmark' Interim Results in Phase 1 ATTR Amyloidosis Trial
New Gene Editing Trial Results Bump the ARKG ETF
Shares of Intellia Therapeutics surged Monday after the firm announced positive results for an in vivo genome editing therapy known as NTLA-2001.
Global Glioblastoma Multiforme (GBM) Treatment Market Could Reach Nearly $1.8 Billion By 2027
/PRNewswire/ — Glioblastoma multiforme (GBM) is one of the areas where the research & development investments are high and where global studies are growing….
Cathie Wood's ARK funds rally on surge in growth stocks
The ARK Innovation fund, which is managed by firm founder Wood, gained 3.5 per cent on Monday and is now up 4.3 per cent for the year to date, highlighting a nearly 31 per cent comeback since hitting its May 13 low
Growth stock comeback fuels Cathie Wood's ARK funds By Reuters
Growth stock comeback fuels Cathie Wood's ARK funds
Intellia Therapeutics : Growth stock comeback fuels Cathie Wood's ARK funds
A more than 10% surge in growth stocks since the start of the quarter is fueling a comeback in star stock picker Cathie Wood's ARK funds, which posted some of the worst declines among all U.S…. | June 29, 2021
Intellia Therapeutics : Growth stock comeback fuels Cathie Wood's ARK funds
A more than 10% surge in growth stocks since the start of the quarter is fueling a comeback in star stock picker Cathie Wood's ARK funds, which posted some of the worst declines among all U.S…. | June 29, 2021
Intellia Therapeutics : Growth stock comeback fuels Cathie Wood's ARK funds
A more than 10% surge in growth stocks since the start of the quarter is fueling a comeback in star stock picker Cathie Wood's ARK funds, which posted some of the worst declines among all U.S…. | June 29, 2021
Intellia Therapeutics : Growth stock comeback fuels Cathie Wood's ARK funds
A more than 10% surge in growth stocks since the start of the quarter is fueling a comeback in star stock picker Cathie Wood's ARK funds, which posted some of the worst declines among all U.S…. | June 29, 2021
Crispr, the Tool Giving DNA Editing Promise and Peril
(Bloomberg) — Mankind has been manipulating genetics since early civilizations realized that certain traits of crops, animals and humans themselves were hereditary.
Intellia Shares Soar on Positive Test Results
GuruFocus Article or News written by Barry Cohen and the topic is about: Merck, Sanofi, Gilead and others stand to benefit from clinical trials
Stock Market Today: Chip Rip Triggers Record Highs in Nasdaq, S&P
Elsewhere, Facebook closed above the $1 trillion market-cap level for the first time ever.
ROUNDUP/Aktien New York Schluss: Rekordlauf geht weiter – Nur Dow Jones im Minus
ROUNDUP/Aktien New York Schluss: Rekordlauf geht weiter – Nur Dow Jones im Minus | Nachricht | finanzen.net
Ignoring Monday's 2 Big Nasdaq Winners Could Cost You Serious Money
Find out why these stocks are climbing higher.
Intellia Shares Climb on Positive Gene-Editing Data
By Matt Grossman
Intellia Therapeutics Inc. shares soared Monday morning after the company reported positive interim data from a Phase 1 clinical study of a gene-editing candidate… | June 28, 2021
Crispr, the Tool Giving DNA Editing Promise and Peril
Mankind has been manipulating genetics since early civilizations realized that certain traits of crops, animals and humans themselves were hereditary. The modern-day mapping of all human genes raised the prospects of learning precisely which genes control which traits and then directly altering their DNA codes. After years of hit-and-miss efforts, a gene-editing system called Crispr that’s cheap, effective and easy to use promises to change our relationship with genetics — for better, worse or b
The Washington Post
Mankind has been manipulating genetics since early civilizations realized that certain traits of crops, animals and humans themselves were hereditary. The modern-day mapping of all human genes raised the prospects of learning precisely which genes control which traits and then directly altering their DNA codes. After years of hit-and-miss efforts, a gene-editing system called Crispr that’s cheap, effective and easy to use promises to change our relationship with genetics — for better, worse or b
Regeneron, Sanofi: EMA To Update Dupixent SmPC With Long-term Safety Data
(RTTNews) – Regeneron Pharmaceuticals Inc. (REGN) and Sanofi (SNYNF, SNY) announced Monday that the European Medicines Agency will update the Dupi…
Dupixent® (dupilumab) SmPC updated with long-term data reinforcing well-established safety profile in adults with moderate-to-severe atopic dermatitis
Dupixent® SmPC updated with long-term data reinforcing well-established safety profile in adults with moderate-to-severe atopic dermatitis Dupixent is the first and only available… | June 28, 2021
Intellia Announces Positive Interim Data On Transthyretin Amyloidosis Study
(RTTNews) – Intellia Therapeutics Inc. (NTLA) and Regeneron Pharmaceuticals Inc. (REGN) announced positive interim data from an ongoing phase 1 c…
Eli Lilly Covid-19 Antibody Drug Shipments Paused Over Variant Concerns
U.S. health officials say the drugmaker’s cocktail isn’t effective against strains that are becoming increasingly common across the country.
4 Hot Stocks to Add to Your Growth Portfolio
With interest rates remaining at near-zero levels, supportive government policies have been driving the growth prospects of several companies. As such…
Regeneron : EC Approves Libtayo For First-line Treatment Of Advanced Non-small Cell Lung Cancer
(RTTNews) – The European Commission has approved the PD-1 inhibitor Libtayo or cemiplimab for the first-line treatment of adults with non-small ce…
Regeneron Pharmaceuticals : Libtayo® (cemiplimab) Approved by the European Commission as the First Immunotherapy Indicated for Patients with Advanced Basal Cell Carcinoma
TARRYTOWN, N.Y. and PARIS, June 25, 2021 /PRNewswire/ —
Approval based on data from the largest trial to date in patients with advanced basal cell carcinoma previously treated with a hedgehog… | June 25, 2021
Libtayo® (cemiplimab) Approved by the European Commission as the First Immunotherapy Indicated for Patients with Advanced Basal Cell Carcinoma
/PRNewswire/ — Approval based on data from the largest trial to date in patients with advanced basal cell carcinoma previously treated with a hedgehog pathway…
Regeneron Pharmaceuticals : Libtayo® (cemiplimab) Approved by the European Commission for First-Line Treatment of Patients with Advanced Non-small Cell Lung Cancer with ≥50% PD-L1 Expression
TARRYTOWN, N.Y. and PARIS, June 25, 2021 /PRNewswire/ —
Approval based on a Phase 3 trial demonstrating Libtayo significantly improved overall survival compared to chemotherapy in advanced… | June 25, 2021